Achillion Pharmaceuticals (ACHN) : 8 analysts are covering Achillion Pharmaceuticals (ACHN) and their average rating on the stock is 2.5, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 2 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Achillion Pharmaceuticals (ACHN) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $17 and the lowest price target forecast is $4. The average forecast of all the analysts is $9.38 and the expected standard deviation is $4.03.
Company shares have received an average consensus rating of Hold for the current week Also, Chardan Capital initiates coverage on Achillion Pharmaceuticals (NASDAQ:ACHN). The shares have now been rated Sell by the stock experts at the ratings house. Chardan Capital announces the current price target of $4 per share on Achillion Pharmaceuticals . The rating by the firm was issued on July 14, 2016.
Achillion Pharmaceuticals (NASDAQ:ACHN): The stock opened at $8.38 and touched an intraday high of $8.49 on Wednesday. During the day, the stock corrected to an intraday low of $8.34, however, the bulls stepped in and pushed the price higher to close in the green at $8.46 with a gain of 1.20% for the day. The total traded volume for the day was 765,891. The stock had closed at $8.36 in the previous trading session.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.